Author: David J. Kerr, CBE, MD, DSc, FRCP, FMedSci Hello. I am David Kerr, professor of cancer medicine from the University of Oxford, England. I want to talk about an interesting paper I picked up recently in Annals of Oncology.[1] This was prepared and presented by Dr Aggarwal from Richard Sullivan’s group at Kings College London. They have done a lot…
Category: Post
Sofosbuvir: A novel treatment option for chronic hepatitis C infection
Author: Harmeet Kaur Bhatia, Harmanjit Singh,1 Nipunjot Grewal,2 and Navreet Kaur Natt3 Abstract Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality. The current standard of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 weeks, along with pegylated…
